DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
OpenAI Restricts Astra AI Over Cyberattack Risks 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
SAN DIEGO, Feb. 27, 2018 -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announced that Dr. Henry Li, a respected expert in preclinical pharmacology, will present a webinar showing data derived from CrownBio’s large-scale immunotherapy screening platform, MuScreen™. The webinar is scheduled for Thursday, March 1, 2018 at 11am EST (5pm CEST).
CrownBio recently completed a comprehensive immunoprofiling study to fast-track the in vivo screening of a panel of 12 commonly used syngeneic models against PD-1/PD-L1 blockade. The analysis of this large study, using both efficacy and immunophenotyping (by flow cytometry on tumor infiltrating immune cells), was conducted for both baseline and pharmacodynamic readouts. The results help address numerous scientific/technical challenges, including a multitude of characteristics for individual syngeneic models and the variations associated with studies using syngeneic models. Attendees will discover how to design and utilize a large-scale, staggered syngeneic platform to address key immuno-oncology questions, improve efficiency and reproducibility of immunotherapy development, all while reducing costs.
“CrownBio strives to provide scientists with predictive solutions that surpass traditional approaches and provide decision making during drug development,” said Dr. Henry Li, CrownBio’s Sr. Vice President of Scientific Research and Innovation. “I am looking forward to presenting conclusive data that shows the utility of our MuScreen platform to accelerate development of immunotherapeutic agents efficiently and cost-effectively.”
Learn more about CrownBio’s large-scale immunotherapy screening platform and sign up to attend the webinar here.
About Crown Bioscience Inc.
CrownBio is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, CrownBio enables clients to deliver superior clinical candidates.
Media Enquiries:
Jody Barbeau
Crown Bioscience Inc.
[email protected]
